Analyst: Novo Nordisk was expected to complete acquisition – despite issues

Though there was trouble along the way, it was no surprise that Novo Nordisk managed to close the billion-dollar acquisition of Dicerna Pharmaceuticals, says an analyst at Sydbank.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

On Tuesday, bets that Novo Nordisk would indeed cross the finish line of the reported USD 3.3bn acquisition of Dicerna Pharmaceuticals could finally be cashed out.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs